PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma.
PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma.
复制标题
PD-L1和IDO1在分化较差的甲状腺癌中表达。
DOI：
10.1007/s12022-018-9514-y
复制
发表时间：
2018-03
影响因子：
4.4
通讯作者：
Faquin WC
中科院分区：
文献类型：
--
作者：
Rosenbaum MW;Gigliotti BJ;Pai SI;Parangi S;Wachtel H;Mino-Kenudson M;Gunda V;Faquin WC
低分化甲状腺癌(PDTC)是一种侵袭性甲状腺癌，目前有效的治疗选择有限。免疫检查点抑制剂(ICIS)已被证明是一种有效的治疗多种癌症的药物。在这项研究中，我们探索免疫检查点通路，如程序性细胞死亡配体1(PD-L1)和吲哚胺2，3-双加氧酶1(IDO1)在PDTC患者队列中是否被激活，以确定ICIS是否可能是这些患者的有效治疗方法。用免疫组织化学方法检测28例PDTC中IDO1、PD-L1和CD8的表达。染色采用H评分，PD-L1和IDO1的表达与临床病理特征相关。PD-L1和IDO1的阳性表达被设定为H分界值5。25%(n=7/28)的PDTC PD-L1表达阳性。29%(n=2/7)的PD-L1阳性PDTCs同时表达IDO1。PD-L1在PDTC中的表达与肿瘤大小和多灶性显著相关，而与年龄、甲状腺外侵犯、有无转移、高分期、CD8+T细胞数量增加、无病生存期和总生存率降低无明显相关。PD-L1的表达发生在PDTC的一个亚群中，并与侵袭性甲状腺疾病的临床特征亚群相关。鉴于对这一人群的有效治疗有限，应该考虑将ICIS作为单一疗法或联合IDO1抑制剂作为PDTC患者的一种新的治疗方式。
Poorly differentiated thyroid carcinoma (PDTC) is an aggressive form of thyroid cancer that currently has limited effective treatment options. Immune checkpoint inhibitors (ICIs) have shown to be an effective treatment for a variety of carcinomas. In this study, we explore whether immune checkpoint pathways, such as Programmed cell death-ligand 1 (PD-L1) and Indoleamine 2,3-dioxygenase 1 (IDO1), are activated in a cohort of patients with PDTC to determine whether ICIs may be an effective therapy for these patients. PDTC from 28 patients were stained for IDO1, PD-L1, and CD8 using immunohistochemistry. Staining was scored using an H-score, and PD-L1 and IDO1 expression was correlated with clinicopathologic characteristics. Positivity for PD-L1 and IDO1 was set at an H-score cutoff of 5. Twenty-five percent (n=7/28) of PDTC were positive for PD-L1 expression. Twenty-nine percent (n =2/7) of PD-L1 positive PDTCs also co-expressed IDO1. Expression of PD-L1 in PDTC was significantly associated with tumor size and multifocality, with a non-significant trend towards associations with older age, extra-thyroidal extension, presence of metastasis, higher stage, increased number of CD8+ T-cells, and decreased disease-free and overall survival. PD-L1 expression occurs in a subset of PDTC, and is associated with a subset of clinical features of aggressive thyroid disease. Given the limited effective treatments for this patient population, consideration for ICIs as monotherapy or in combination with an IDO1 inhibitor should be explored as a novel treatment modality for patients with PDTC.
登录
查看更多内容
影响因子：
3.5
作者：
Lee, SJ;Jang, BC;Choi, IH
通讯作者：
Choi, IH
DOI：
10.1016/s1470-2045(16)30364-3
发表时间：
2016-10
期刊：
The Lancet. Oncology
影响因子：
--
作者：
Kaufman HL;Russell J;Hamid O;Bhatia S;Terheyden P;D'Angelo SP;Shih KC;Lebbé C;Linette GP;Milella M;Brownell I;Lewis KD;Lorch JH;Chin K;Mahnke L;von Heydebreck A;Cuillerot JM;Nghiem P
通讯作者：
Nghiem P
影响因子：
--
作者：
Brauner E;Gunda V;Vanden Borre P;Zurakowski D;Kim YS;Dennett KV;Amin S;Freeman GJ;Parangi S
通讯作者：
Parangi S
IV期或复发性非小细胞肺癌中的一线Nivolumab。
DOI：
10.1056/nejmoa1613493
发表时间：
2017-06-22
期刊：
The New England journal of medicine
影响因子：
--
作者：
Carbone DP;Reck M;Paz-Ares L;Creelan B;Horn L;Steins M;Felip E;van den Heuvel MM;Ciuleanu TE;Badin F;Ready N;Hiltermann TJN;Nair S;Juergens R;Peters S;Minenza E;Wrangle JM;Rodriguez-Abreu D;Borghaei H;Blumenschein GR Jr;Villaruz LC;Havel L;Krejci J;Corral Jaime J;Chang H;Geese WJ;Bhagavatheeswaran P;Chen AC;Socinski MA;CheckMate 026 Investigators
通讯作者：
CheckMate 026 Investigators
DOI：
10.1056/nejmoa1200694
发表时间：
2012-06-28
期刊：
The New England journal of medicine
影响因子：
--
作者：
Brahmer JR;Tykodi SS;Chow LQ;Hwu WJ;Topalian SL;Hwu P;Drake CG;Camacho LH;Kauh J;Odunsi K;Pitot HC;Hamid O;Bhatia S;Martins R;Eaton K;Chen S;Salay TM;Alaparthy S;Grosso JF;Korman AJ;Parker SM;Agrawal S;Goldberg SM;Pardoll DM;Gupta A;Wigginton JM
通讯作者：
Wigginton JM